{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:43:41Z","timestamp":1768545821147,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anti-platelet agents are commonly used in vasospastic angina (VA) patients with comorbidity like coronary artery disease. However, long-term clinical outcomes in the use of aspirin, clopidogrel or the two agents together have rarely been investigated in VA patients. In a prospective study, we enrolled 2960 patients who received coronary angiography and ergonovine provocation test at 11 university hospitals in Korea. Among them, 1838 patients were diagnosed either with definite (n\u2009=\u2009680) or intermediate (n\u2009=\u20091212) VA, using the criteria of chest pain, ECG changes and ergonovine provocation test results. They were analyzed according to their use of aspirin, clopidogrel or both, or no anti-platelet agent at all. The primary outcome was time to composite events of death from any cause, acute coronary syndrome (ACS) and symptomatic arrhythmia during a 3-year follow-up. A primary composite outcome was significantly more common in the aspirin plus clopidogrel group, at 10.8% (14\/130), as compared with the non-antiplatelet group, at 4.4% (44\/1011), (hazard ratio [HR] 2.41, 95% confidence interval [CI], 1.32\u20134.40, p\u2009=\u20090.004). With regard to the person-time event rate, similar results were shown, with the highest rate in the aspirin plus clopidogrel user at 4.72\/1000 person months (95% CI, 2.79\u20137.96, log-rank test for primary outcome p\u2009=\u20090.016). The person-time event of the ACS rate was also highest in that group, at 2.81 (95% CI, 1.46\u20135.40, log-rank test for ACS p\u2009=\u20090.116). Kaplan-Meier survival analysis demonstrated poor prognosis in primary outcomes and ACS in aspirin plus clopidogrel users (log-rank test, p\u2009=\u20090.005 and p\u2009=\u20090.0392, respectively). Cox-proportional hazard regression analysis, adjusting for age, sex, history of coronary heart disease, hypertension, diabetes, presence or not of definite spasm, use of calcium channel blocker, demonstrated that the use of aspirin plus clopidogrel is an independent risk for the primary outcome (HR 2.01, CI: 1.07\u20133.81, p\u2009=\u20090.031). The aspirin-alone group had a similar primary and individual event rate compared to the no-antiplatelet agent group (HR 0.96, CI, 0.59\u20131.55, p\u2009=\u20090.872). Smokers using aspirin plus clopidogrel had poorer outcomes than non-smokers, with HR 6.36 (CI 2.31\u201317.54, p\u2009=\u20090.045 for interaction). In conclusion, among VA patients, aspirin plus clopidogrel use is associated with a poor clinical outcome at 3 years, especially in ACS. Aspirin alone appears to be safe for use in those patients.<\/jats:p>","DOI":"10.1038\/s41598-019-54390-w","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T11:03:21Z","timestamp":1574939001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Clopidogrel plus Aspirin Use is Associated with Worse Long-Term Outcomes, but Aspirin Use Alone is Safe in Patients with Vasospastic Angina: Results from the VA-Korea Registry, A Prospective Multi-Center Cohort"],"prefix":"10.1038","volume":"9","author":[{"given":"Seong-Sik","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2063-1542","authenticated-orcid":false,"given":"Sang-Ho","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Hwan","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwan Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Ho","family":"Her","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0748-7766","authenticated-orcid":false,"given":"Min-Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won-Woo","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Hyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keun-Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Won","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byoung-Kwon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Woon","family":"Rha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon-Cheol","family":"Gwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Hong","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"key":"54390_CR1","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.jcin.2014.12.249","volume":"8","author":"DI Shin","year":"2015","unstructured":"Shin, D. I. et al. The 24-Month Prognosis of Patients With Positive or Intermediate Results in the Intracoronary Ergonovine Provocation Test. JACC Cardiovasc. Interv. 8, 914\u2013923 (2015).","journal-title":"JACC Cardiovasc. Interv."},{"key":"54390_CR2","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/0002-9149(81)90249-6","volume":"47","author":"K Miwa","year":"1981","unstructured":"Miwa, K., Kambara, H. & Kawai, C. Exercise-induced angina provoked by aspirin administration in patients with variant angina. Am. J. Cardiol. 47, 1210\u20131214 (1981).","journal-title":"Am. J. Cardiol."},{"key":"54390_CR3","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1056\/NEJM197805182982005","volume":"298","author":"P Needleman","year":"1978","unstructured":"Needleman, P. & Kaley, G. Cardiac and coronary prostaglandin synthesis and function. N Engl J Med. 298, 1122\u20131128 (1978).","journal-title":"N Engl J Med."},{"key":"54390_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0002-8703(83)90548-3","volume":"105","author":"K Miwa","year":"1983","unstructured":"Miwa, K., Kambara, H. & Kawai, C. Effect of aspirin in large doses on attacks of variant angina. Am. Heart J. 105, 351\u2013355 (1983).","journal-title":"Am. Heart J."},{"key":"54390_CR5","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/S0140-6736(79)92877-0","volume":"2","author":"K Miwa","year":"1979","unstructured":"Miwa, K., Kambara, H. & Kawai, C. Variant angina aggravated by aspirin. Lancet 2, 1382 (1979).","journal-title":"Lancet"},{"key":"54390_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ijcard.2016.06.195","volume":"221","author":"AY Lim","year":"2016","unstructured":"Lim, A. Y. et al. Clinical implications of low-dose aspirin on vasospastic angina patients without significant coronary artery stenosis; a propensity score-matched analysis. Int. J. Cardiol. 221, 161\u2013166 (2016).","journal-title":"Int. J. Cardiol."},{"key":"54390_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1253\/circj.71.220","volume":"71","author":"S Fuke","year":"2007","unstructured":"Fuke, S. et al. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ. J. 71, 220\u2013225 (2007).","journal-title":"Circ. J."},{"key":"54390_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1253\/circj.CJ-15-1202","volume":"80","author":"JF Beltrame","year":"2016","unstructured":"Beltrame, J. F. et al. The Who, What, Why, When, How and Where of Vasospastic Angina. Circ. J. 80, 289\u2013298 (2016).","journal-title":"Circ. J."},{"key":"54390_CR9","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.ijcard.2012.11.010","volume":"167","author":"MC Kim","year":"2013","unstructured":"Kim, M. C. et al. Clinical outcomes of low-dose aspirin administration in patients with variant angina pectoris. Int. J. Cardiol. 167, 2333\u20132334 (2013).","journal-title":"Int. J. Cardiol."},{"key":"54390_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jjcc.2012.02.007","volume":"60","author":"JY Park","year":"2012","unstructured":"Park, J. Y. et al. Impact of low-dose aspirin on coronary artery spasm as assessed by intracoronary acetylcholine provocation test in Korean patients. J. Cardiol. 60, 187\u2013191 (2012).","journal-title":"J. Cardiol."},{"key":"54390_CR11","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1161\/01.ATV.0000225288.74170.dc","volume":"26","author":"T Heitzer","year":"2006","unstructured":"Heitzer, T. et al. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler. Thromb. Vasc. Biol. 26, 1648\u20131652 (2006).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"54390_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijcard.2017.06.099","volume":"248","author":"TK Rudolph","year":"2017","unstructured":"Rudolph, T. K. et al. Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris: A randomized controlled trial. Int. J. Cardiol. 248, 7\u201313 (2017).","journal-title":"Int. J. Cardiol."},{"key":"54390_CR13","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/01.fjc.0000211795.45281.9d","volume":"48","author":"M Kanko","year":"2006","unstructured":"Kanko, M., Ozden, M., Maral, H. & Acil, C. Effect of clopidogrel on nitric oxide levels in an ischemia reperfusion model. J. Cardiovasc. Pharmacol. 48, 797\u2013801 (2006).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"54390_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/00005344-200401000-00012","volume":"43","author":"MM Arrebola","year":"2004","unstructured":"Arrebola, M. M. et al. In vitro effects of clopidogrel on the platelet-subendothelium interaction, platelet thromboxane and endothelial prostacyclin production, and nitric oxide synthesis. J. Cardiovasc. Pharmacol. 43, 74\u201382 (2004).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"54390_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.atherosclerosis.2015.07.009","volume":"242","author":"G Siasos","year":"2015","unstructured":"Siasos, G. et al. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy. Atherosclerosis 242, 102\u2013108 (2015).","journal-title":"Atherosclerosis"},{"key":"54390_CR16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jcmg.2011.12.019","volume":"5","author":"AP Chirumamilla","year":"2012","unstructured":"Chirumamilla, A. P. et al. High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. JACC Cardiovasc Imaging 5, 540\u2013549 (2012).","journal-title":"JACC Cardiovasc Imaging"},{"key":"54390_CR17","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","volume":"382","author":"GW Stone","year":"2013","unstructured":"Stone, G. W. et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382, 614\u2013623 (2013).","journal-title":"Lancet"},{"key":"54390_CR18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jjcc.2015.06.013","volume":"66","author":"IH Lee","year":"2015","unstructured":"Lee, I. H., Kim, H. & Je, N. K. Underutilization of warfarin for stroke prophylaxis in patients with atrial fibrillation or atrial flutter in Korea. J. Cardiol. 66, 475\u2013481 (2015).","journal-title":"J. Cardiol."},{"key":"54390_CR19","doi-asserted-by":"crossref","unstructured":"Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013). Circ. J. 78, 2779\u20132801 (2014).","DOI":"10.1253\/circj.CJ-66-0098"},{"key":"54390_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.repc.2013.10.017","volume":"33","author":"BC Galvao","year":"2014","unstructured":"Galvao, B. C. et al. New-onset atrial fibrillation during acute coronary syndromes: predictors and prognosis. Rev. Port. Cardiol. 33, 281\u2013287 (2014).","journal-title":"Rev. Port. Cardiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54390-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54390-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54390-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:37:09Z","timestamp":1671295029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54390-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["54390"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-54390-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"19 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17783"}}